Cancer Genetic initial public offerings : The U.S. genetic anti-cancer company Cancer Genetics which was founded in 1999, submitted applications to SEC on 2011 December 30 and intended to raise fund of $50 million meanwhile trade the company’s shares on the Nasdaq stock exchange with the symbol “CGIX”. According to disclosed document F1, the Cancer Genetics’ sales reached $3 million in the past 12 months ended on December 30, 2011. Read more about Cancer Genetic IPO.
The Company continued the losses in the past five consecutive years, and the revenues of 2006 was just $826 thousand. The losses continuously closed to or exceeded the same period revenue levels. The 2010 annual loss was $8.407 million, three times over its annual revenue.
The company realized revenues of $2.14 million in the first nine months in 2011, which was 33.58% higher than the same period of the last year, while the losses reached $16.8 million, rose sharply than the same period value of $7.24 million in 2010.
Best stock watch.com Cancer Genetic IPO watch